In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent

Bittermann T, Reddy KR. In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent. Clin Gastroenterol Hepatol. 2020;S1542-3565(20):31294-5.

Publication Type:

Journal Article

Authors:

Bittermann, T; Reddy, KR

Source:

Clin Gastroenterol Hepatol, Volume S1542-3565, Issue 20, p.31294-5 (2020)

Cited On:

Patients With Decompensated Cirrhosis

Export Citation:

RIS Format

Top